



4500 San Pablo Road
Jacksonville, Florida
32224
904-953-4647
Tax ID: 59-3337028

March 5, 2025

Dear Exhibitor,

On behalf of course directors, Gerardo Colon-Otero, M.D., Rami Manochakian, M.D., and Swapna M. Kochuveetil, APRN, D.N.P., we hope you will consider a display opportunity at our 34th Annual Mayo Clinic Hematology/Oncology Reviews held July 31 - August 2, 2025 at The Ritz-Carlton Amelia Island. We expect 400+ practicing hematologists, medical oncologists, scientists, researchers, nurses, physician assistants, pharmacists and clinical research associates.

This course is a comprehensive review of hematology/oncology that focuses on the clinical application of new research developments over the preceding year. Attendees will leave with up-to-date, practical information which will have immediate clinical application. The most important clinical management questions in hematology/oncology will also be addressed in highly interactive sessions. The speakers are nationally and internationally recognized specialists in the field. Both live, in-person and virtual exhibit options are available. Please note, this course is offering additional sponsorship opportunities outside of the booths.

Live Exhibit Benefits:

- Promotion available at the live three-day course
- Exhibitors are provided the same meals and beverages provided to registered attendees
- Attendees are encouraged daily by the course moderator to visit and connect with the exhibitors
- Includes a 6ft table, two chairs and linen at the course
- An attendee list including registered attendee's name, degree, specialty, city, state, and demographics distributed post course
- Vendor recognition in online course syllabus for all registered attendees to access
- An acknowledgement on the break slide announcements during the course

Virtual Exhibit Benefits:

- Promotion available from the time a company signs the LOA and exhibit booth website is built until one year from the last day of the course, 8/1/2026
- Listing in the online exhibitor directory linked to your company website and landing page (listing will be alphabetical)
- Exhibit booth customization, options include PowerPoint slide, PDF handout or video
- Post course report providing analytics on page traffic
- An attendee list including registered attendee's name, degree, specialty, city, state, and demographics distributed post course
- Vendor Recognition in the online course syllabus
- An acknowledgement on the break slide announcements during the course

- Provided two complimentary access for two conference web links – no credit can be claimed and no access to course materials included
- To maintain a clear separation of promotion from education, the virtual exhibit opportunity will be available on a separate webpage tab than where course materials are accessible.

Sponsorship and Exhibit Opportunities:

| Premier Sponsorship Opportunities | Gold \$27,000 | Silver \$13,500 | Bronze \$9,000 | Live Exhibit Only \$5,500 | Virtual Exhibit Only \$3,000 |
|--|---|--|---|-------------------------------------|-------------------------------------|
| Number of Spots Available | 2 | 5 | 18 | | |
| Waived Fee for Conference Bag Insert | X | | | | |
| Signage at breakfasts and lunches | X | X | | | |
| Virtual Exhibit Booth | X | X | X | | X |
| Exhibit Table | 2 - 6 ft. tables (premium location) <i>First Table Selections</i> | 1 - 6 ft. table (premium location) <i>Second Table Selections after Gold group</i> | 1 - 6 ft. table (premium location) <i>Third Table Selections after Silver group</i> | 1 - 6 ft. table (standard location) | N/A |

Additional Sponsorship Opportunities:

Welcome Reception Sponsor - \$10,000 per company (Limited to 3 Companies)

We invite you to display your company logo for all Attendees to see during the Welcome Reception/Fellows Research Posters Session. Your sponsorship includes prominent signage outside the reception area as well as inside the ballroom. Your company will provide a high-resolution logo to be printed on physician signage and used in a digital signage on televisions.

Internet - \$7,000 (Exclusive)

Help attendees stay connected with their office and home while away at the 34th Annual Hematology/Oncology Reviews 2025. Sponsor the wireless internet access in the meeting space. The supporter will be recognized throughout the meeting in signage and electronic communications.

Conference Bags - \$5,000 (Exclusive)

Display your company logo for all Attendees to see and announce your presence at the conference. Your company will provide a high-resolution logo to be printed on conference bags ordered by managing committee. All bags will contain flyers and advertisements from other participants. (Artwork to be provided by sponsoring company and is subject to MCSCPD approval)

Conference Bag Inserts - \$2,500

Conference bag inserts are a great opportunity to invite attendees to your booth, announce your booth participation or conference-related event. Your company will provide 350 copies of the flyer or advertisement (no larger than 8 ½ x 11, no more than one page) and MCSCPD will place them into the official conference bags.

Mayo Clinic, an integrated, not-for-profit group practice, is committed to meeting its responsibility as a national medical education resource. In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Our programs provide valuable information on unmet needs to the medical community. We sincerely appreciate your consideration and hope you will take the opportunity to join us for a truly unique educational program.

Sincerely,

Kelly Tanner
Education Administration Coordinator

Make checks payable to:

Mayo Clinic CPD

Attn: 25J01185

4500 San Pablo Road

Stabile 790N - Education

Jacksonville, FL 32224

Tax ID: 59-3337028

Request for Taxpayer Identification Number and Certification

Go to www.irs.gov/FormW9 for instructions and the latest information.

**Give form to the
requester. Do not
send to the IRS.**

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

| | |
|--|--|
| Print or type. See <i>Specific Instructions</i> on page 3. | <p>1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.)</p> <p>Mayo Clinic Jacksonville</p> <p>2 Business name/disregarded entity name, if different from above.</p> <p>3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only one of the following seven boxes.</p> <p><input type="checkbox"/> Individual/sole proprietor <input type="checkbox"/> C corporation <input type="checkbox"/> S corporation <input type="checkbox"/> Partnership <input type="checkbox"/> Trust/estate</p> <p><input type="checkbox"/> LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) _____</p> <p>Note: Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner.</p> <p><input checked="" type="checkbox"/> Other (see instructions) 501 (c) (3) Tax-exempt Nonprofit Corporation</p> <p>3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions <input type="checkbox"/></p> <p>4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):</p> <p>Exempt payee code (if any) 1</p> <p>Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any) A</p> <p style="text-align: right;"><i>(Applies to accounts maintained outside the United States.)</i></p> <p>5 Address (number, street, and apt. or suite no.). See instructions.</p> <p>4500 San Pablo Road</p> <p>6 City, state, and ZIP code</p> <p>Jacksonville, FL 32224</p> <p>7 List account number(s) here (optional)</p> <p>Requester's name and address (optional)</p> |
|--|--|

Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

Note: If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

| | | | | | | | | | |
|---------------------------------------|---|---|---|---|---|---|---|---|---|
| Social security number | | | | | | | | | |
| | | | | | | | | | |
| or | | | | | | | | | |
| Employer identification number | | | | | | | | | |
| 5 | 9 | - | 3 | 3 | 3 | 7 | 0 | 2 | 8 |

Part II Certification

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

| | | | | |
|------------------|--------------------------|----------------------|------|------------|
| Sign Here | Signature of U.S. person | <i>Katy Domaille</i> | Date | 01/02/2025 |
|------------------|--------------------------|----------------------|------|------------|

General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

What's New

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they

34th Annual Hematology/Oncology Reviews
25th Annual Fellows' Research Presentations
Ritz-Carlton, Amelia Island, Florida
July 31 – August 2, 2025

Thursday, July 31, 2025

| | |
|---|---|
| 7:00 a.m. | Registration and Continental Breakfast |
| 7:50 | Welcome and Review of Course with Pre-Test Gerardo Colon-Otero, M.D. (MCF) and Rami Manochakian, M.D. (MCF) |
| Session: Non-Malignant Hematology | |
| Moderator: Ewa Wysokinska, M.D. (MCF) | |
| 8:20 | Update on Management of Thrombosis Leslie Padrnos, M.D. (MCA) |
| 8:40 | Update on Management of thrombotic microangiopathy Meera Sridharan M.D, Ph.D (MCR) |
| 9:00 | Update on new drugs in classical hematology Marwan Shaikh, M.D. (MCF) |
| 9:20 | Q&A |
| 9:45 | Break |
| Session: CLL & Multiple Myeloma | |
| Moderator: Asher Chanan-Khan, M.B.B.S., M.D. (MCF) | |
| 10:05 | Update on Management of Chronic Lymphocytic Leukemia (CLL) Ricardo Parrondo, M.D. (MCF) |
| 10:25 | Update on Management of Multiple Myeloma Sikander Ailawadhi, M.D. (MCF) |
| 10:45 | Q&A |
| 11:05 | Break |
| Session: Acute Leukemias | |
| Moderator: James Foran, M.D. (MCF) | |
| 11:25 | Update on Management of Acute Myelogenous Leukemia (AML) Razan Mohty, M.D. (University of Alabama) |
| 11:45 | Update on Management of Acute Lymphoblastic Leukemia (ALL) James Foran, M.D. (MCF) |
| 12:05 | Q&A |
| 12:25 | Lunch: Elective Session for Extended Q&A with Morning Speakers |
| Session: Chronic Myeloid Disorders (CMPN and MDS) | |
| Moderator: James Foran, M.D. (MCF) | |
| 1:25 | Update on Management of Chronic Myeloproliferative Neoplasms (CMPN) Candido Rivera, M.D. (MCF) |
| 1:45 | Update on Management of Chronic Myelogenous Leukemia (CML) Lindsay Rein, M.D. (Duke) |
| 2:05 | Update on Management of Myelodysplastic Syndromes (MDS) Hemant Murthy, M.D. (MCF) |
| 2:25 | Q&A |
| 2:50 | Break |
| Session: Lymphomas | |
| Moderator: Thomas Habermann, M.D. (MCR) | |
| 3:10 | Update on Management of CD30+ Lymphomas (T cell and Hodgkin) Madiha Iqbal, M.D. (MCF) |
| 3:30 | Update on Management of Low-grade Non-Hodgkin Lymphoma Carrie Thompson, M.D (MCR) |
| 3:50 | Update on Management of Aggressive Lymphomas Muhamad Alhaj Moustafa, M.D. (MCF) |
| 4:10 | Q&A |
| 4:35 | Break |

Program schedule is subject to change without notice.

34th Annual Hematology/Oncology Reviews

25th Annual Fellows' Research Presentations

Ritz-Carlton, Amelia Island, Florida

July 31 – August 2, 2025

Continuing Thursday, July 31, 2025

**Session: Case-Based Discussion on optimizing management of patients with hematologic malignancies
(collaboration between community and academic centers)**

Lucio Gordan, M.D. (Florida Cancer Specialists), Ernesto Ayala, M.D. (MCF), Mohamed Kharfan Dabaja, M.D., M.B.A. (MCF)

| | |
|------|-----------------------|
| 4:40 | Case-Based Discussion |
| 5:30 | Adjourn |

Friday, August 1, 2025

| | |
|---|--|
| 7:00 a.m. | Continental Breakfast |
| 7:50 | Day 2 Welcome and Pre-Test |
| Session: GU Oncology | |
| Moderator: Winston Tan, M.D. (MCF) | |
| 8:10 | Update on Management of Bladder Cancer Adam Kase, M.D (MCF) |
| 8:30 | Update on Management of Renal Cell Cancer Maria Carlo, M.D. (MSK) |
| 8:50 | Update on Management of Metastatic Prostate Cancer Winston Tan, M.D. (MCF) |
| 9:10 | Q&A |
| 9:35 | Break |
| Session: Head & Neck Cancers, and Melanoma | |
| Moderator: Rami Manochakian, M.D (MCF) | |
| 9:55 | Update on Management of Head & Neck Cancers Yujie Zhao, M.D., Ph.D. (MCF) |
| 10:15 | Update on Management of Melanoma Roxana Dronca, M.D. (MCF) |
| 10:35 | Q&A |
| 10:55 | Break |
| Session: GYN Oncology and Sarcoma | |
| Moderator: Gerardo Colon-Otero, M.D. (MCF) | |
| 11:15 | Update on Management of Gynecologic Oncology Cancers Stephanie Gaillard, M.D. (John Hopkins) |
| 11:35 | Update on Management of Sarcoma Neeta Somaiah, M.D (MD Anderson) |
| 11:55 | Q&A |
| 12:15 | Lunch: Elective Session for Extended Q&A with Morning Speakers |
| Session: GI Oncology | |
| Moderator: Jeremy Jones, M.D. (MCF) | |
| 1:15 | Update on Management of Metastatic Colorectal Cancer Christina Wu, M.D. (MCA) |
| 1:35 | Update on Management of Potentially Resectable Rectal Cancer Jeremy Jones, M.D. (MCF) |
| 1:55 | Update on Management of Gastroesophageal Cancers Mustafa Tehfe, M.D (University of Montreal) |
| 2:15 | Q&A |

Program schedule is subject to change without notice.

34th Annual Hematology/Oncology Reviews

25th Annual Fellows' Research Presentations

Ritz-Carlton, Amelia Island, Florida

July 31 – August 2, 2025

| Continuing Friday, August 1, 2025 | |
|--|---|
| 2:40 p.m. | Break |
| 3:00 | Update on Management of Pancreas Cancer Hani Babiker, M.D. (MCF) |
| 3:20 | Update on Management of Hepatobiliary Cancers Umair Majeed, M.B.B.S, M.D. (MCF) |
| 3:40 | Update on Management of Neuroendocrine Tumors Jason Starr, D.O. (MCF) |
| 4:00 | Q&A |
| 4:25 | Adjourn |
| 6:00 – 8:00 | Fellows Research Posters Viewing/Discussion & Welcome Reception |

| Saturday, August 2, 2025 | |
|---|---|
| 7:00 a.m. | Continental Breakfast |
| 7:50 | Day 3 Welcome |
| Session: Lung Cancer | |
| Moderator: Rami Manochakian, M.D. (MCF) | |
| 8:00 | Update on Management of Advanced Non-Small Cell Lung Cancer without Targetable Mutations Vamshi Velcheti (MCF) |
| 8:20 | Update on Management of Advanced Non-Small Cell Lung Cancer with Targetable Mutations Natasha Leighl, M.D. (Princess Margaret Cancer Center, University of Toronto) |
| 8:40 | Q&A |
| 9:00 | Update on Management of Early-Stage NSCLC Shenduo Li, M.D, Ph.D (MCF) |
| 9:20 | Update on Management of Small Cell Lung Cancer Yanyan Lou, M.D., Ph.D (MCF) |
| 9:40 | Q&A |
| 10:00 | Break |
| Special Session: Case-Based Discussion & Controversy | |
| Lung Cancer Panel Speakers | |
| 10:15 | Case-Based Discussion & Q&A |
| 11:05 | Break |
| Session: Breast Cancers | |
| Moderator: Pooja Advani, M.B.B.S., M.D. (MCF) | |
| 11:15 | Update on Management of Triple Negative Breast Cancer Erika Hamilton, M.D. (Sarah Cannon) |
| 11:35 | Update on Management of Her2 Positive Breast Cancer Sarah Chumsri, M.D (MCF) |
| 11:55 | Update on Management of Hormone Receptor Positive Breast Cancer Pooja Advani, M.B.B.S., M.D. (MCF) |
| 12:15 | Q&A |
| 12:40 | Adjourn (Lunch Provided) |

Program schedule is subject to change without notice.



School of Continuous
Professional
Development

34th Annual Mayo Clinic Hematology & Oncology Reviews 2025

& 25th Annual Fellows' Research Presentations

July 31, 2025 to August 2, 2025

REGISTER TODAY!

The Ritz-Carlton
Amelia Island, Florida



20.25
AMA PRA
Category 1
Credits™,
ANCC Nursing
Contact Hours

ce.mayo.edu/hemonreview2025

COURSE HIGHLIGHTS

- Comprehensive review of hematology and oncology that focuses on the application of new clinical and research advancements over the preceding year.
- Attendees will leave with up-to-date, practical information that has immediate clinical application.
- The most important clinical management questions are addressed in highly interactive sessions.

TARGET AUDIENCE

Practicing hematologists, medical oncologists, scientists, researchers, nurses, physician assistants, pharmacists and clinical research associates and trainees.

LEARNING OBJECTIVES

Upon conclusion of this program, participants should be able to:

- List new practice-changing developments in hematology and medical oncology in 2024-2025.
- Identify benefits and risks of new hematology/oncology treatments (drugs and combinations) approved by the FDA.
- Describe the most important management issues in hematology and oncology.
- Describe the results of the latest practice changing clinical trials in hematology/oncology.

COURSE DIRECTORS

Gerardo Colon-Otero, M.D.
Rami Manochakian, M.D.
Swapna M. Kochuveetil, APRN, D.N.P.



REGISTRATION FEES

| | Registration on or Before 6/14/2025 | Registration after 6/14/2025 |
|---|-------------------------------------|------------------------------|
| M.D., D.O., Scientist | \$700 | \$775 |
| Resident, Fellow, NP, PA, Allied Health Professional, Retiree | \$575 | \$650 |

ce.mayo.edu/hemoncreviews2025

LODGING & ACCOMMODATIONS

The Ritz-Carlton, Amelia Island
4750 Amelia Island Pkwy
Fernandina Beach, FL 32034

The reservation link will be emailed to attendees after registration. The room block sells out very quickly. Early registration is encouraged.

Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 20.25 ANCC nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PROGRAM AT A GLANCE

THURSDAY, JULY 31, 2025

Non-Malignant Hematology

- Update on Management of Thrombosis
- Update on Management of Thrombotic Microangiopathy
- Update on New Drugs in Classical Hematology

CLL & Multiple Myeloma

- Update on Management of Chronic Lymphocytic Leukemia (CLL)
- Update on Management of Multiple Myeloma

Acute Leukemias

- Update on Management of Acute Myelogenous Leukemia (AML)
- Update on Management of Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Disorders (CMPN and MDS)

- Update on Management of Chronic Myeloproliferative Neoplasms (CMPN)
- Update on Management of Chronic Myelogenous Leukemia (CML)
- Update on Management of Myelodysplastic Syndromes (MDS)

Lymphomas

- Update on Management of CD30+ Lymphomas (T-cell and Hodgkin)
- Update on Management of Low-grade Non-Hodgkin Lymphoma
- Update on Management of Aggressive Lymphomas

FRIDAY, AUGUST 1, 2025

GU Oncology

- Update on Management of Bladder Cancer
- Update on Management of Renal Cell Cancer
- Update on Management of Metastatic Prostate Cancer

Head & Neck Cancers and Melanoma

- Update on Management of Head & Neck Cancers
- Update on Management of Melanoma

GYN Oncology and Sarcoma

- Update on Management of Gynecologic Oncology Cancers
- Update on Management of Sarcoma

GI Oncology

- Update on Management of Metastatic Colorectal Cancer
- Update on Management of Potentially Resectable Rectal Cancer
- Update on Management of Gastroesophageal Cancer
- Update on Management of Pancreas Cancer
- Update on Management of Hepatobiliary Cancers
- Update on Management of Neuroendocrine Tumors

Fellows' Research Posters Discussion & Welcome Reception

SATURDAY, AUGUST 2, 2025

Lung Cancer

- Update on Management of Advanced Non-Small Cell Lung Cancer without Targetable Mutations
- Update on Management of Advanced Non-Small Cell Lung Cancer with Targetable Mutations
- Update on Management of Early-Stage NSCLC
- Update on Management of Small Cell Lung Cancer

Breast Cancers

- Update on Management of Hormone Receptor Positive Breast Cancer
- Update on Management of Her2 Positive Breast Cancer
- Update on Management of Triple Negative Breast Cancer



34th Annual Mayo Clinic Hematology & Oncology Reviews 2025

REGISTER TODAY!

JULY 31, 2025 TO AUGUST 2, 2025

**The Ritz Carlton
Amelia Island, FL**

ce.mayo.edu/hemoncreview2025



Mayo Clinic School of Continuous Professional Development

ce.mayo.edu | cme@mayo.edu | 800-323-2688

Imagery is copyright Mayo Clinic, Getty Images, Shutterstock or approved for use.

©2025 Mayo Foundation for Medical Education and Research.

MC8100-05BR0rev0225

Mayo Clinic
200 First Street SW
Rochester, MN 55905

ELECTRONIC SERVICE REQUESTED

NON-PROFIT ORG.
U.S. POSTAGE
PAID
MAYO CLINIC